Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | KEYNOTE-866: pembrolizumab + chemotherapy for bladder cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the KEYNOTE-866 trial (NCT03924856), which investigated perioperative pembrolizumab plus neoadjuvant chemotherapy versus perioperative placebo plus neoadjuvant chemotherapy for cisplatin-eligible muscle-invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.